Star Pharmaceutical delists from main board of SGX

The company will acquire its remaining shares.

Star Pharmaceutical Holdings will be delisted from the main board of Singapore Exchange Securities Trading Limited (SGX-ST) on 6 December, according to an SGX filing.

Star Pharmaceutical has said in its proposed delisting on 15 November, that it wishes to exercise its right of compulsory acquisition, and be the sole shareholder of the company.

The company will be effectively delisted from the board upon completion of the purchase of the remaining shares.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia